Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| MM1MDS-A01 | Alliance | A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MM1OA-EA02 | ECOG-ACRIN | A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MM1YA-S01 | SWOG | A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial | Adult CIRB - Late Phase Emphasis | Available to Open | |
| MyeloMATCH | SWOG | Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials | Adult CIRB - Late Phase Emphasis | Available to Open | |
| N0147 | NCCTG | A Randomized Phase III Trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| N0434 (MA.27D) | NCCTG | The Association of Breast Density Changes; Plasma Hormone Changes; and<br>Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27 | Adult CIRB - Late Phase Emphasis | Available to Open | |
| N0574 | NCCTG | Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases | Adult CIRB - Late Phase Emphasis | Available to Open | |
| N0577 | NCCTG | N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| N0723 | NCCTG | MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib | Adult CIRB - Late Phase Emphasis | Completed | |
| N0949 | NCCTG | Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab Versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First-line Treatment in Elderly Patients with Metastatic Colorectal Cancer | Adult CIRB - Late Phase Emphasis | Completed |